Chronic renal ischemia: Pathophysiologic mechanisms of cardiovascular and renal disease

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 11, 2002, Pages 1085-1092

  Rundback, John H ^a   Murphy, Timothy P ^b   Cooper, Christopher ^c   Weintraub, Joshua L ^a  

^a NewYork Presbyterian Hospital   (United States)

^b BROWN UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Hypertension, renovascular; Kidney, blood supply; Renal arteries, stenosis or obstruction

Indexed keywords

CYTOKINE; FREE RADICAL; VASOACTIVE AGENT;

ADRENERGIC STIMULATION; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY ISCHEMIA; NATRIURESIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REPERFUSION; REVIEW;

EID: 0036850304     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61948-4     Document Type: Review

References (92)

1. Romero JC, Feldstein AE, Rodriguez-Porcel MG, Cases-Amenos A. New insights into the pathophysiology of renovascular hypertension, Mayo Clin Proc 1997; 72:251-260.
2. Jacobson HR. Ischemic renal disease: An overlooked clinical entity? Kidney Int 1988; 34:729-743.
3. Breyer JA, Jacobson HR. Ischemic nephropathy. Curr Opin Nephrol Hypertens 1993; 2:216-224.
4. Simon N, Franklin SS, Bleifer KH, Maxwell MH. Clinical characteristics of renovascular hypertension. JAMA 1972; 220:1209-1218.
5. Sawicki PT, Kaiser S, Heinemann L, Frenzei H. Prevalence of renal artery stenosis in diabetes mellitus - An autopsy study. J Int Med 1991; 229:489-492.
6. O’Neil EA, Hansen KJ, Canzanello VJ, Pennell TC, Dean RH. Prevalence of ischemic nephropathy in patients with renal insufficiency. Am Surg 1992; 58:485-490.
7. Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int 1995; 48:171-176.
8. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT, Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis 1994; 24:622-629.
9. Fatica RA, Port FK, Young EW. Incidence trends and mortality in endstage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001; 37:1184-1190.
10. Losito A, Parente B, Cao PG, Jeffery S, Afzal AR. ACE gene polymorphism and survival in atherosclerotic renovascular disease. Am J Kidney Dis 2000; 35:211-215.
11. Isles CG, Robertson S, Hill D. Management of renovascular disease: A review of renal artery stenting in ten studies. QJM 1999; 92:159-167.
12. Conlon PJ, O’Riordan E, Kalra PA. New insights into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease. Am J Kidney Dis 2000; 35:573-587.
13. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 2001; 60:1490-1497.
14. Goldblatt HL, Hanzal RF, Summerville WW. Studies on experimental hypertension: I - The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59:347-380.
15. Brown JJ, Davies DL, Morton JJ, et al. Mechanism of renal hypertension. Lancet 1976; 1(7971):1219-1221.
16. Anderson WP, Korner PI. The importance of renal vascular tone in determining the severity of renal artery stenosis in dogs. J Physiol 1980; 305:31-41.
17. Nafz B, Berthold H, Ehmke H, Hackenthal E, Kirchheim HR, Persson PB. Flow versus pressure in the control of renin release in conscious dogs. Am J Physiol 1997; 273(part 2):F200-F205.
18. Textor SC, Novick AC, Tarazi RC, Klimas V, Vidt DG, Pohl M. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308-314.
19. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233:F366-F372.
20. May AG DJ, Rob CG. Hemodyanamic effects of arterial stenosis. Surgery 1963; 53:513-524.
21. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the reninangiotensin system. Circulation 1993; 87:1816-1628.
22. van Velzer DA, Burge CH, Morris GC. Arteriosclerotic narrowing of renal arteries associated with hypertension. AJR AM J Roentgenol 1961; 85:807-818.
23. Webb RC, Kiron MA, Rosenberg E, Soffer RL. Antiserum to angiotensin-binding protein inhibits vascular responses to angiotensin II. Am J Physiol 1988; 255:H1542-H1544.
24. Romero JC, Reckelhoff JF. State-of-the-art lecture: Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34(part 2):943-949.
25. Korner PI. Cardiovascular hypertrophy and hypertension: Causes and consequences. Blood Press Suppl 1995; 2:6-16.
26. Anderson WP, Korner PI, Angus JA, Johnston CI. Contribution of stenosis resistance to the rise in total peripheral resistance during experimental renal hypertension in conscious dogs. Clin Sci (Colch) 1981; 61:663-670.
27. Schoenberg SO, Bock M, Kallinowski F, Just A. Correlation of hemodynamic impact and morphologic degree of renal artery stenosis in a canine model. J Am Soc Nephrol 2000; 11:2190-2198.
28. Pipinos II, Nypaver TJ, Moshin SK, Careterro OA, Beierwaltes WH. Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. J Vasc Surg 1998; 28:167-177.
29. Korner PI. The sixth Volhard Lecture: Causal and homoeostatic factors in hypertension. Clin Sci (Colch) 1982; 63(suppl 8):5S-26S.
30. Imanishi M, Ohta M, Akabane S, et al. Aspirin injection test to predict angioplasty outcome in unilateral renovascular hypertension: Preliminary report. Clin Invest Med 1991; 14:566-573.
31. Imanishi M, Tsuji T, Nakamura S, Takamiya M. Prostaglandin I(2)/E(2) ratios in unilateral renovascular hypertension of different severities. Hypertension 2001; 38:23-27.
32. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999; 10(suppl 12):S266-S272.
33. Gonzalez-Campoy JM, Long C, Roberts D, Berndt TJ, Romero JC, Knox FG. Renal interstitial hydrostatic pressure and PGE2 in pressure natriuresis. Am J Physiol 1991; 260(part 2):F643-F649.
34. Milot A, Lambert R, Lebel M, Cusson JR, Larochelle P. Prostaglandins and renal function in hypertensive patients with unilateral renal artery stenosis and patients with essential hypertension. J Hypertens 1996; 14:765-771.
35. Mattson DL, Wu F. Control of arterial blood pressure and renal sodium excretion by nitric oxide synthase in the renal medulla. Acta Physiol Scand 2000; 168:149-154.
36. Tullis MJ, Zierler RE, Caps MT, Bergelin RO, Cantwell-Gab K, Strandness DE Jr. Clinical evidence of contralateral renal parenchymal injury in patients with unilateral atherosclerotic renal artery stenosis. Ann Vasc Surg 1998; 12:122-127.
37. Della Bruna R, Bernhard I, Gess B, Schricker K, Kurtz A. Renin gene and angiotensin II AT1 receptor gene expression in the kidneys of normal and of two-kidney/one-clip rats. Pflugers Arch 1995; 430:265-272.
38. Rossi GP, Pavan E, Chiesura-Corona M, et al. Renovascular hypertension with low-to-normal plasma renin: Clinical and angiographic features. Clin Sci (Colch) 1997; 93:435-443.
39. Navar LG, Harrison-Bernard LM. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res 2000; 23:291-301.
40. Nickenig G, Strehlow K, Roeling J, Zolk O, Knorr A, Bohm M. Salt induces vascular AT1 receptor overexpression in vitro and in vivo. Hypertension 1998; 31:1272-1277.
41. Rimmer JM. The consequences of renal artery stenosis. Hosp Pract (Off Ed) 1994; 29:29-32,35,39-42.
42. Connolly JO, Higgins RM, Walters HL, et al. Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. QJM 1994; 87:413-421.
43. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249(part 2):F324-F337.
44. Molitoris BA. The potential role of ischemia in renal disease progression. Kidney Int Suppl 1992; 36:S21-S25.
45. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24:642-651.
46. Scoble JE. Atherosclerotic nephropathy. Kidney Int Suppl 1999; 71:S106-S109.
47. Farmer CK, Cook GJ, Blake GM, Reidy J, Scoble JE. Individual kidney function in atherosclerotic nephropathy is not related to the presence of renal artery stenosis. Nephrol Dial Transplant 1999; 14:2880-2884.
48. Volpe M, Camargo MJ, Mueller FB, et al. Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension 1990; 15:318-326.
49. Kobayashi S, Ishida A, Moriya H, Mori N, Fukuda T, Takamura T. Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. J Lab Clin Med 1999; 133:134-143.
50. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril induced functional renal insufficiency in patients with bilateral renal artery stenosis or stenosis in solitary kidney. N Engl J Med 1983; 308:373-376.
51. Grone JH, Helmchen U. Impairment and recovery of clipped kidney in two kidney one clip hypertensive rats during and after hypertensive therapy. Lab Invest 1986; 54:645-655.
52. Hollenberg NK. Medical therapy of renovascular hypertension: A review. Am J Hypertens 1988; 1(4 pt 2):S338-S343.
53. Morgan T, Wilson M, Johnston W, Clunie GJ, Gordon R. Restoration of renal function by arterial surgery. Lancet 1974; 1:653-656.
54. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24:642-651.
55. Gobe G, Axelsen R, Searle JW. Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest 1990; 63:770-779.
56. Kim S, Outa K, Hamaguchi I, et al. Contribution of renal angiotensin II type I receptor to gene expression in hypertension induced renal injury. Kidney Int 1994; 46:1346-1358.
57. Johnson RJ, Alpers LE, Yoshimura A, et al. Renal injury from angiotensin II mediated hypertension. Hypertension 1992; 19:464-474.
58. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1998; 7:2495-2508.
59. Maschio G, Alberti D, Janin G, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
60. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of ACE-Inhibition in arresting progressive renal disease associated with systolic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
61. Woods RL, Anderson WP, Korner PI. Renal and systemic effects of enalapril in chronic one-kidney hypertension. Hypertension 1986; 8:109-116.
62. Selig SE, Anderson WP, Korner PI, Casley DJ. The role of angiotensin II in the development of hypertension and in the maintenance of glomerular filtration rate during 48 hours of renal artery stenosis in conscious dogs. J Hypertens 1983; 1:153-158.
63. Huang WC, Tsai RY, Fang TC. Nitric oxide modulates the development and surgical reversal of renovascular hypertension in rats. J Hypertens 2000; 18:601-613.
64. Dedeoglu IO, Springate JE. Effect of nitric oxide inhibition on kidney function in experimental renovascular hypertension. Clin Exp Hypertens 2001; 23:267-275.
65. Higashi T, Kobayashi N, Hara K, Shirataki H, Matsuoka H. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol 2000; 35:564-571.
66. Rizzoni D, Porteri E, Castellano M, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998; 31(part 2):335-341.
67. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001.
68. Poch E, Jimenez W, Feu F, et al. Increased plasma endothelin concentration in atherosclerotic renovascular hypertension. Nephron 1995; 71:291-296.
69. Teunissen KE, Postma CT, van Jaarsveld BC, Derkx FH, Thien T. Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. J Hypertens 1997; 15(part 2):1791-1796.
70. Ehmke H, Faulhaber J, Munter K, Kirchengast M, Wiesner RJ. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 1999; 33:954-960.
71. Bianciotti LG, de Bold AJ. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension. Cardiovasc Res 2001; 49:808-816.
72. Schiffrin EL. State-of-the-art lecture: Role of endothelin-1 in hypertension. Hypertension 1999; 34(part 2):876-881.
73. Gavras H, Lever AF, Brown JJ, Macadam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; 2(7714):19-22.
74. Yamazaki T, Shiojima I, Komuro I, Nagai R, Yazaki Y. Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction. J Hypertens Suppl 1994; 12:S153-S157.
75. Hocher B, George I, Rebstock J, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:816-822.
76. Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992; 19:25-32.
77. Wang C, Dobrzynski E, Chao J, Chao L. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol 2001; 280:F964-F971.
78. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis: Relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999; 17:1743-1750.
79. Gao SA, Johansson M, Rundqvist B, Lambert G, Jensen G, Friberg P. Reduced spontaneous baroreceptor sensitivity in patients with renovascular hypertension. J Hypertens 2002; 20:111-116.
80. Rauch AL, Campbell WG. Synthesis of catecholamines in the hypothalamus and brainstem in two-kidney one clip hypertension in rabbits. J Hypertens 1988; 6:537-541.
81. Salazar FJ, Quesada T. Mechanisms of experimental and human renovascular hypertension. In: Luscher TF, Kaplan NM, eds. Renovascular and Renal Parenchymatous Hypertension. New York: Springer-Verlag, 1992;107-136.
82. Johansson M, Elam M, Rundqvist B, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99:2537-2542.
83. Ganong WF, ed. Review of Medical Physiology, 11th Ed. Los Altos, CA: Lange Medical Publications, 1983.
84. Harder DR, Lange AR, Gebremedhin D, Birks EK, Roman RJ. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res 1997; 34:237-243.
85. Farber HW, Center DM, Rounds S. Bovine and human endothelial cell production of neutrophil chemoattractant in response to components of the angiotensin system. Circ Res 1985; 57:898-902.
86. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
87. Fukunaga M, Yura T, Badr KF. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol 1995; 26(suppl 3):S51-S52.
88. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37(part 2):541-546.
89. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346:1954-1962.
90. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
91. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000; 342:145-153.
92. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens 1998; 12:295-259.